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Diagnosis and Management of Tachycardias After Myocardial
Infarction

Charles R. Webb, MD*

T

he patient with acute myocardial infarction (MI) may present with acute arrhythmias due to ischemia as well as
chronic arrhythmias such as chronic atrial fibrillation or ventricular ectopy. The only way to distinguish acute, chronic, or paroxysmal arrhythmia is by a careful history from the patient and
review of available old records. Guidelines for the diagnosis and
determination of the significance of arrhythmia afler acute MI
are presented herein.

Rationale for Therapy
The three purposes for treating a patient for arrhythmia are:
1) relief of symptoms due to the arrhythmia, 2) suppression of
arrhythmia causing hemodynamic impairment, and 3) prevention of related and potentially lethal arrhythmias.
The management of an arrhythmia begins with determination
ofits prognosis and hemodynamic implications and detection of
any potential causative factors before initiation of specific antiarrhythmic pharmacologic therapy.
Antiarrhythmic therapy should be individualized regarding
choice of agent, dosage, and length of therapy. Some cases require acule therapy for arrhythmia termination. Others require
chronic arrhythmia prevention or suppression. For some arrhythmias, such as chronic atrial fibrillation or chronic premature ventricular complexes, there may be no effective means of
lermination. Therefore, control of arrhythmia frequency or rate
must be accepted.
Determination of such individualized therapeutic goals or targets will allow u.se of minimal effective dmg dosages, thereby
minimizing side effects, toxicity, and cost.

Recognition of Precipitating or Exacerbating
Noncardiovascular Factors
For diagnostic and therapeutic purposes, arrhythmias may be
called primary if due to cardiac pathology, or secondary if reactive to a systemic or myocardial process. To delermine if and
when to treat the arrhythmia, the first question which must be
answered is whether the arrhythmia is a primary illness, merely
refiects more basic cardiovascular dysfunction, or is the result of
systemic or metabolic imbalance.
Hypoxia can cause or exacerbate almost any atrial or ventricular arrhythmia (I). Arrhythmia often results from membrane
instability which reflects more generalized electrolyte imbalance. Hypokalemia must be appropriately corrected particularly

226

Henry Ford Hosp Med J—Vol ,39, Nos 3 & 4, 1991

for patients taking diuretics (2). Since potassium is primarily an
intracellular ion, merely correcting the serum potassium may
not be adequate and days to weeks may be required for complete
correction. In the interim period, specific antiarrhythmic drug
therapy is not likely to be effective. Anecdotally, it seems that a
serum potassium level of 4.0 mEq/L or higher is necessary to
stabilize arrhythmias in certain patients with cardiovascular disease.
Hypomagnesemia also predisposes to arrhythmias and lends
to make antiarrhythmic drugs less effective (3,4). Like potassium, magnesium is an intracellular ion, and correction of the
serum level may precede total body equilibrium by several days.
Occasionally ectopy and tachyarrhythmias, including refractory
or incessant ventricular tachycardia (VT), appear to be suppressed by magnesium, even when the serum level is already
normal.
Hypokalemia and hypomagnesemia should be suspected in
any patient with chronic or acute diuretic therapy, particularly
without ionic supplementation, or patients with poor or restricted diets, malabsorption, or diarrhea.
Heart failure is associated with arrhythmia (5,6). Ventricular
ectopy and nonsustained or sustained VT often are improved or
abolished with appropriate diuresis, inotropic therapy (7) (digoxin), and/or vasodilator therapy (8). In the cardiac intensive
care setting, the pulmonary capillary wedge pressure, pulmonary and vascular resistances, and cardiac output can be optimized by therapy guided by right heart catheterization (SwanGanz catheterization).
Arrhythmia preceded by chest pain or transient electrocardiographic ST or T-wave changes is often due to myocardial
ischemia. These arrhythmias often respond to antiischemic drug
therapy (nitrates, P-adrenergic blockade, calcium channel antagonists), coronary angioplasty, or bypass surgery. Paradoxically, in the period immediately after angioplasty (9), thrombolytic therapy, or relief of Prinzmetal's vasospastic angina
(10), arrhythmias may recur or appear de novo. These are called
reperfusion arrhythmias. They should be suppressed with lidocaine or procainamide intravenously and should resolve within
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24 hours. When arrhythmias occur later after angioplasty, the
possibility of ischemia due to reocclusion of a dilated vessel
must be considered.
Ventricular arrhythmias commonly complicate acute MI.
Acutely, any significant ventricular ectopy should be suppressed by a lidocaine bolus of 50 to 100 mg intravenously followed by an infusiontitratedbetween 2 to 4 pg/min. Sustained
arrhythmias such as ventricular fibrillation within the first 24
hours do not portend chronic arrhythmic propensity, and once
arrhythmia is resolved and the patient leaves the critical care
unit, routine cardiac monitoring and rehabilitation guidelines
should be followed (11,12).
Pericarditis (postinfarction or Dressler's syndrome) may
mimic, complicate, or follow acute Ml. It usually presents as
chest pain, classically with a pericardial friction rub and a small
pleural effusion. Pericarditis is frequently associated with atrial
arrhythmias and less commonly ventricular arrhythmias, which
usually respond to antiinflammatory therapy and natural resolution of the acute process. Because of the proximity of the sinus
node to the epicardium, sinus node suppression and bradyarrhythmias may also occur (13).
Cardiac manifestations may be the only physical evidence of
thyroid disease in the elderly or critically ill patient. Patients
with persistent sinus tachycardias in the absence of congestive
heart failure should have thyroid disease excluded by a serum
thyroid-stimulating hormone determination (14).
Many dmgs may cause or exacerbate cardiac arrhythmias. Diuretics may induce hypokalemia and/or hypomagnesemia as
discus.sed above. Digoxin may suppress arrhythmias if cardiac
function is improved: however, an excess may exacerbate or
cause almost any cardiac arrhythmia. Bradycardia and heart
block are the most obvious of these, particularly when digoxin
is combined with ^-adrenergic blockade or calcium channel
blocking drugs. However, ventricular ectopy, VT, or ventricular
fibrillation may occur. It is important to recognize that these
arrhythmias are due to digoxin toxicity because the appropriate
therapy is optimization of electrolytes, correction of hypoxia,
cessation of digoxin therapy, and occasionally dialysis or intravenous administration of digoxin antibodies. On the other hand,
specific antiarrhythmic drug therapy is unlikely to be effective.
Cardioversion for atrial arrhythmias or VT is hazardous because
digoxin lowers the ventricular fibrillation threshold. The digoxin therapeutic toxic dose ratio is small and variable. Although markedly elevated serum levels correlate well with toxicity, there are usually obvious clinical symptoms or signs in
such cases. In more subtie cases, the serum drug levels are likely
to be borderline. This is probably due to variable cardiac sensitivity related to the underlying type and severity of cardiac disease and variations in the electrolytic and metabolic milieu
(15,16). When an antiarrhythmic drug is necessary for suppression of ventricular arrhythmia, diphenylhydantoin has the advantage of moderate efficacy as a membrane stabilizer and the
least negative dromotropic effect on the cardiac conduction system. It is the least likely to exacerbate heart block.
Bronchodilators, particularly the methylated xanthines, commonly exacerbate arrhythmias. In the critically ill patient, previously well tolerated agents tend to accumulate and serum levels
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should routinely be assessed. The only reliable antidote appears
to be reduction of dosage; specific antiarrhythmic therapy is unlikely to be useful.
The patient's hospital and clinic charts must be reviewed for
any "antiarrhythmic" therapy. Indeed, there is no antiarrhythmic
agent which uniformly decreases arrhythmic potential. Most
agents are effective for suppression of ectopy in about 60% of
patients and for prevention of sustained arrhythmia in about
30% of patients. In general, any antiarrhythmic agent has the
propensity to worsen arrhythmias in 10% to 15% of patients
(17). Obviously, for the patient who has arrhythmia while on antiarrhythmic medication, the drug is not antiarrhythmic at the
current dosage level. When consulted because of arrhythmia in
a patient already receiving chronic antiarrhythmic therapy, first
review the history to determine why the therapy was instituled.
Ifthe patient has a history of lethal arrhythmias and only ectopy
is noted currently, perhaps the therapeutic goal of prevention of
lethal arrhythmia is indeed being fulfilled and therapy should be
continued. However, if a patient has potentially lethal or lethal
cardiac arrhythmia while on chronic antiarrhythmic therapy,
peak and trough drug levels should be evaluated. Subtherapeutic levels would require an increase in dosage and reassessment
of antiarrhythmic efficacy after a new steady-state blood level is
attained (after administration of the new dose for five drug halflives). On the other hand, levels above the usual therapeutic
level call for reduction of dosage and reassessment of arrhythmia after five drug half-lives. If the drug level is within the therapeutic range, it is usually advisable to discontinue the current
agent and employ a different agent. In difficult cases, combination drug therapy is beneficial. Success has been reported with
combinations of Vaughn-Williams class lA and IB agents (18).
Combination of IA and IC agents is contraindicated as arrhythmic deaths have been reported (19). In fact, when switching between these subclasses of drugs, it is safest to eliminate the first
agent entirely, before initiation of the second agent.

The Supraventricular Arrhythmias
The most common arrhythmia accompanying acute Ml is sinus tachycardia. Sinus tachycardia is recognized by P waves
which precede each QRS complex in a 1:1 ratio with an appropriate PR interval. Each P wave is upright in electrocardiographic leads II, III, and AVF, indicating a craniocaudal sequence of atrial depolarization. Carotid sinus pressure results in
transient, gradual slowing wilh retum to the previous rate seconds afterrelea.se.
Usually sinus tachycardia is due to anxiety or is an appropriate cardiovascular response to pain or disease and seldom
should be suppressed with antiarrhythmic drugs. Digoxin at
therapeutic levels is rarely effective in suppressing a normal
sinus node (20). However, |3-adrenergic blockers or calcium
channel blockers may blunt an appropriate chronotropic response and result in hemodynamic collapse.
Hypovolemia is a common cause of sinus tachycardia and the
heart rate should diminish gradually as plasma volume is restored. Relative hypovolemia may be due to decreased left ventricular compliance or ventricular infarction which can be de-
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lected by Swan-Ganz catheterization. Other causes are anxiety,
fear, pain, anemia, fever, hyperthyroidism or thyrotoxicosis,
overdose of thyroid replacement, vagolytic drugs (atropine),
vasopressors (isoproterenol, dobutamine, dopamine), vasodilators (nitrates, procardia), and antihypertensives.
Some degree of sinus arrhythmia is common. Unless long
symptomatic pauses occur, it is not an indication for specific
therapy.
Atrial premature complexes (APCs) are common in any hyperadrenergic state that is commonly associated with sinus
tachycardia. Usually the P-wave morphology is different from
sinus P waves indicafing that the focus is ectopic, not the sinus
node. However, some foci are near or within the sinus perinodal
tissue and may appear similar to sinus node-initiated P waves.
Generally APCs are asymptomatic and the therapy should be directed at correction of the systemic disease process as, more often than not, the heart is merely an innocent bystander. Caffeine
and methylated xanthines and vasopressors commonly are responsible and their dosages should be minimized. Hypoxia, hypovolemia, anemia, and electrolyte imbalance should be corrected. Rarely is specific antiarrhythmic therapy indicated unless APCs are symptomatic or perceived as harbingers to atrial
fi utter or fibrillafion in patients with a history of such arrhythmia.
Atrial tachycardia is an arrhythmia which originates in the
atria. Therefore, each ventricular complex is preceded by an
atrial complex with an appropriate PR interval. The P-wave
morphology is uniform, usually ectopic, and different than sinus
P waves. Carotid sinus pressure may terminate the arrhythmia
abmptly. Ectopic atrial tachycardia is rarely of hemodynamic
significance and does not require specific therapy.
Multifocal atrial tachycardia is a common cardiac manifestation of serious acute cardiac or pulmonary disease. It is an irregulariy irregular arrhythmia characterized by the triad of varying
P-wave morphologies, varying P to P intervals, and varying PR
intervals (21). Carotid sinus pressure usually has no effect on the
arrhythmia. Its distinction from atrialflutteror fibrillation is important. Digoxin is contraindicated because the factors which
perpetuate multifocal atrial tachycardia also predispose to digoxin toxicity and proarrhythmia. i.e., hypoxia and electrolyte
imbalance. Some investigators report relative success with calcium channel blockers. However, the most effective therapy is
detection and correction of the underiying cause.
Atrial flutter is characterized by uniform P waves at a rate of
300 to 350 beats/min. It is associated with rapid mechanical
atrial activity. There is discrete electrical and mechanical systole
and diastole. Usually the atrioventricular (AV) node is effective
as a filter resulting in a physiologic 2:1 or higher AV nodal
block and a moderated ventricular rate of about 150 to 200
beats/min. Any rhythm at a rate of 150 beats/min should result
in consideration of atrial flutter with examinafion of rhythm
strips and a 12-Iead ECG for P waves. (Caution: P waves may be
small and hide on the QRS complex or in the T waves. They tend
to become more visible at early morning staff rounds than at
night.) Careful examination of the neck veins for A waves may
make the diagnosis. Movement of the V leads an interspace
higher or lower than usual or even to the back may detect P
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waves and make the diagnosis. Carotid sinus pressure may transiently increase the AV nodal block and make the P waves visible. Rarely, insertion of an intraatrial lead is necessary to make
the diagnosis.
Atrialfluttermay be a primary arrhythmia in patients with no
other evidence of cardiac or systemic disease. More frequently,
however, it is secondary to congestive heart failure, cardiomyopathy, pericarditis, pulmonary disease, cardiac surgery, hypertension, alcohol, smoking, or caffeinated beverages. Occasionally patients present with heart failure secondary to a sustained
episode of paroxysmal atrial flutter.
Three basic forms of therapy are available for termination of
sustained atrial flutter. Atrial overdrive pacing is an invasive
procedure involving insertion of an intraatrial electrode which
is useful to confirm the diagnosis and for terminafion (22,
23). When the atrium is carefully entrained and pacing abruptly stopped, sinus rhythm should prevail, but there is always
the possibility of proarrhythmia, resulting in atrial fibrillation
which often converts to sinus rhythm spontaneously within 24
hours. The advantage of atrial overdrive pacing is that it is rapid
and avoids administration of dmgs which are potentially negative inotropes in critically ill patients. A brachial vein approach
is safe for patients who are on low-dose anticoagulation therapy,
even in outpatients whom 1 send to work after two hours of observation. Digoxin toxicity is not a contraindication.
When the rate of the atrium duringfiutteris greater than 210
beats/min, entrainment of the atrium may not be possible. In
such cases, the refractory period of the atrium may be increased
by prior oral or intravenous administration of a Vaughn-Williams type IA antiarrhythmic agent.
Intravenous procainamide, 500 to 1,000 mg, by intravenous
infusion over 20 minutes, is often effective. This dosage requires constant patient supervision and blood pressure monitoring at least every 5 minutes. Hypotension frequentiy results, occasionally because of negative inotropic effect, but more commonly because of peripheral vasodilatation which responds to
reduction of infusion rate by half and administration of 100 to
200 mL of normal saline rapidly. Depending on the estimated
likelihood of early recurrence, the infusion may be either terminated upon restoration of normal sinus rhythm or reduced to 2 to
4 mg/min until oral loading is initiated. Oral loading of digoxin
and subsequently a quinidine preparation may also be effective,
but it takes longer (days rather than minutes). Quinidine has a
potent vagolytic effect on the AV node and can accelerate the
ventricular rate to 200 beats/min or higher due to 1:1 AV nodal
conduction unless the AV node is first blocked with digoxin or
a (i-adrenergic blocker. However, the vagolytic effect of procainamide is nol of clinical significance and previous administration of digoxin is not a prerequisite.
The third method of acute termination of atrial flutter is cardioversion. It is often said that low energy cardioversion (10 to
25 joules) is effecfive for atrialflutter,but frequentiy higher energy is necessary. Cardioversion is uncomfortable with sedation
and there is hazard of respiratory suppression in the critically
ill patient. Brief general anesthesia with the ultrashort-acting
agent, methohexital, 40 to 100 mg intravenously,titratedunder
supervision of an anesthetist is our preferred method of car-
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dioversion. Cardioversion should not be attempted if there is
electrolyte imbalance or suspicion of digoxin toxicity.
If an acute precipitating factor for atrial arrhythmia can be
identified and corrected, the patient is usually followed chronically without antiarrhythmic therapy or given digoxin to control
the ventricular response if atrial flutter recurs. When chronic
therapy is desired, digoxin is the basis and a type IA antiarrhythmic agent such as quinidine gluconate, sustained-release procainamide, or disopyramide is given. Preliminary data suggest
that flecainide, encainide, and propaphenone are effective for
chronic prevention and by slowing the ventricular rate if flutter
should recur. However, according to the results of the Cardiac
Arrhythmia Suppression Trial, these agents must be avoided in
the patient with recent or acute MI. Amiodarone is also highly
effective, but its delayed onset of action, long half-life, and potential toxicity prevents recommendation unless other agents
have failed or are not tolerated.
Atrial fibrillation is characterized by a chaotic electrical
baseline on the ECG. There is no distinct electrical systole or diastole and no effective mechanical contraction of the atria.
Rarely, fibrillation is isolated to one atrium. Because there is no
effective mechanical activity, there is a high propensity to
thrombus formation and cerebrovascular embolization is one of
the most severe complications. The cardiac output may be diminished by 10% to 25% depending on atrial size and effectiveness and the ventricular compliance. In cardiovascular disease
with a stiff left ventricle such as asymmetric septal hypertrophy,
restrictive cardiomyopathy, or severe aortic stenosis, development of atrial fibrillation may result in hemodynamic collapse.
Thus the assessment of atrial fibrillation should include a complete cardiovascular evaluation including an echocardiogram to
evaluate atrial size and to search for obvious intramural atrial
thrombi.
There are two potential mechanisms of atrial fibrillation. One
is a rapid chaotic atrial discharge which suppresses a normal sinus node; the other is an escape mechanism in the presence of a
diseased sinus node which results in severe bradycardia or long
pauses. In the former instance, if the abnormal atrial fibrillation
is electrically, pharmacologically, or spontaneously terminated,
normal sinus rhythm supervenes. In the sick sinus syndrome,
however, the abnormal atrial arrhythmia may be a vital escape
mechanism and its termination may reveal impaired or absent
sinus node activity. Whenever this situation is predicted by previous ECGs demonstrating significant bradycardia, sinus pause
or arrest, or junctional or lower escape mechanism, electrical or
chemical cardioversion should be preceded by placement of a
temporary or permanent transvenous pacemaker.
Acute versus chronic arrhythmia
It is essential to determine the premorbid arrhythmia to determine appropriate therapy and predict outcome. All old ECGs
should be reviewed to determine thefimeof onset of atrial fibrillation, the underlying baseline rhythm, and whether atrial fibrillation is a lone event that is unlikely to recur for a long time after
successful restoration of normal rhythm or is paroxysmal and
likely to be recurrent without therapy in the future. An old
Holler monitor may document significant 3-second pauses or
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symptomatic pauses with a lower junctional escape rhythm
demonstrating that a pacemaker should be implanted.
As a "grandfathered" standard of clinical care, the recent literature is devoid of precise statistics on the "odds" of successful
cardioversion to normal sinus rhythm. In the individual patient,
clinical experience dictates that the acuteness of onset is a good
predictor of success, whereas cardioversion is only occasionally
successful for atrial fibrillation of six months duration. Atrial
size by echocardiography also plays a role, but there are major
limitations to accurate atrial measurements by echocardiography. Treatment and reversal of a precipitating cause is a good
predictor, i.e., thyroxine excess, congestive heart failure, alcohol consumption, exposure, electrolyte imbalance, antiarrhythmic dmg noncompliance. High amplitude "flutter waves" in the
baseline imply that the atrium is electrically active and suggest
more recent onset and easier cardioversion.
Once these matters have been considered, the basic alternatives for conversion are electrical and pharmacologic. The
choice should be based upon informed patient preference and
availability of personnel and facilities.
Pharmacologic therapy has the advantage of determining effective long-term therapy and can be initiated on any telemetrymonitored hospital floor with oral or intravenous drug administration.
If atrial fibrillation is of recent onset, correction of precipitating causes and restoration of normal sinus rhythm is desirable.
If rapid pharmacologic termination is desired, intravenous
procainamide is administered, just as described for atrial fiutter
(24). Verapamil may slow the ventricular response, but seldom,
if ever, terminates atrial fibrillafion to restore normal sinus
rhythm (25). Use of verapamil may be complicated by hypotension and impaired cardiac output.
If an oral pharmacologic approach is preferred, digoxin is
usually administered to control the ventricular response. Oral
quinidine sulfate, quinidine gluconate, or sustained-release procainamide is then added. 1 do not advocate high dosage therapy
as the likelihood of conversion to sinus rhythm is not assured,
but risk of side effects or toxicity is likely.
Cardioversion is effective for atrial fibrillation of recent onset
after exacerbating factors are resolved (26). If atrial fibrillation
has persisted for two or more weeks, four to six weeks of anticoagulation therapy is required to prevent microthrombi which
might be dislodged during cardioversion. The technique is similar to the description for atrial flutter, except that higher energy
levels are used, beginning with 100 joules. Our laboratory makes
an attempt at 100,200, and 360 joules wilh sufficient time for recovery and monitoring of vital signs between shocks.
If precipitating faclors can be identified, chronic antiarrhythmic therapy may not be required for the first episode (27). However, if arrhythmia is recurrent, digoxin is useful to help control
the ventricular rate. Type IA antiarrhythmic therapy is useful for
prevention of atrial fibrillation. In the absence of recent M l or
ischemia, flecainide, encainide, and propaphenone alone or in
combination with digoxin have been successful in prevention or
modulation of paroxysmal atrial flbriOation.
For atrial fibrillation of more than six months duration or
which has failed to respond to pharmacologic or electrical car-
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dioversion, control of the ventricular rate is accomplished with
digoxin which may be titrated safely according to ventricular
rate in atrial fibrillation, occasionally requiring unusually high
dosages. Addition of other AV nodal blockers may be required
to modulate the ventricular rate including p-adrenergic blocking
agenls, calcium channel blocking agents, or amiodarone (28).
In patients refractory to antiarrhythmic drug therapy, catheter
or surgical modulation of the AV node may be required (29). If
AV nodal ablation is required or results inadvertently, a permanent ventricular pacemaker is required. This is not all bad. Implantation of a newer rate-responsive pacemaker may restore a
degree of appropriate chronotropic responsiveness simulating a
sinus node which the chronic atrial fibrillator has never before
enjoyed. Guiradon and coworkers (30.31) are developing surgical conduit techniques to restore sinovenlricular communication. This technique can restore chronotropic function but not
atrial mechanical function. Cox et al (32) are developing a
"maze" procedure to disrupt the reentrant electrical pathways of
atrial fibrillation and restore normal sinus rhythm and transport
function.
AV nodal leentrant tachycardia is a common tachycardia
usually characterized by a narrow QRS complex with retrograde
P waves which are more often than not buried within the QRS
complex or distorting the terminal portion of it. Occasionally a
rate-dependent (usually right) bundle branch QRS pattem results. Carotid sinus pressure may transiently slow or terminate
the tachycardia abruptly. Usually the atrial rate is 140 to 210
beats/min with the symptoms and hemodynamic consequences
dependenl on the rate. It is common in patients with no evidence
of cardiovascular disease. Intravenous digoxin or procainamide
are effective for acute termination, as are atrial or ventricular
pacing techniques which may also be of diagnostic value. Interestingly, although the reentrant arrhythmia circuit is confined to
the AV node (animal studies have shown that resection of atria
and ventricles does not terminate the tachycardia), type IA antiarrhythmic agents are effective in blocking the retrograde limb
of the tachycardia (33,34).
Generically, tachycardias may be classified into three groups
based on duration alone: paroxysmal, persistent, or chronic.
Arrhythmias which are paroxysmal may be of any mechanism,
including VT. By definition, torsade de pointes is paroxysmal.
Paroxysmal atrial tachycardia describes any atrial arrhythmia
which lasts only seconds to hours. It is a mistake to develop a
management plan for paroxysmal atrial tachycardia, because it
is not a specific diagnosis but a syndrome which may include
AV nodal reentrant tachycardia, sinus tachycardia, or atrial fibrillation. When the mechanism is determined, specific therapy
follows logically.

Wide QRS Tachycardia
A wide QRS tachycardia associated with hypotension during
acute MI is considered to be VT and is treated as such until
proven otherwise.
In the setfing of acute MI or acute ischemic syndrome, wide
complex tachycardia must be terminated immediately. How-
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ever, in the absence of acute MI if the hemodynamics and symptomatology permit, appropriate recording, documentation, and
assessment are essential because the arrhythmia is likely to recur, but perhaps never again in a controlled monitored setting
such as the cardiac intensive care unit. The initial electrocardiographic recording during the acule event facilitates appropriate
in-hospital evaluation and long-term outpatient management.
Termination without adequate documentation can result in uncertainly of diagnosis, delay hospital discharge, and confound
the chronic management plan.
Wide complex tachycardia is defined as a cardiac dysrhythmia having a rate greater than 100 complexes per minute (or RR cycle length less than 600 msec) and a QRS duration greater
than 120 msec in any lead on a standardized 12-lead ECG. For
descriptive purposes, the QRS morphology during tachycardia
is assigned a bundle branch block pattem (left or right or normal). A right bundle branch block pattem is assigned if the QRS
complex is predominantiy positive in lead V I ; prominent terminal negative S waves in leads I and V5 or V6 are supportive findings. A left bundle branch block pattem is assigned when the
intrinsicoid deflection is delayed in the lateral electrocardiographic leads (1, and V5 or V6); usually V I is predominantiy
negative. The tachycardia may be further characterized by the
predominant or mean QRS axis during the tachycardia: normal
axis i f i l lies between 0 and 90 degrees; left axis deviation if it is
less than 0 degrees; or right axis deviation if it is greater than 90
degrees. This classification scheme does not necessarily imply
mechanism or origin of tachycardia but serves as a catalog to determine wheiher there is recurrence of the same tachycardia or
perhaps tachycardias of different types in the same patient, each
of which may require specific therapy. For example, a patient
may have a polymorphous tachycardia due to ischemia or electrolyte imbalance which will not require chronic therapy and another monomorphic tachycardia due to a reentrant focus (either
supraventricular or ventricular) which is likely to recur after
hospital discharge and requires chronic therapy.
A 12-lead ECG machine, cardiorespiratory resuscitative
drugs and equipment, and a defibrillator should be brought to
the bedside in case cardioconversion is required for emergent
termination of life-threatening arrhythmia.
The differential diagnosis of a regular wide complex tachycardia includes: I) supraventricular tachycardia with a functional bundle branch block, 2) supraventricular tachycardia with
a preexistent bundle branch block, 3) supraventricular tachycardia with antegrade AV conduction over an accessory AV pathway (antidromic supraventricular tachycardia), or 4) VT.
Age, heart rate, blood pressure, level of consciousness, and
duration or presence or absence of heart disease are not accurate
determinants of the tachycardia mechanism. VT is the most common mechanism of wide QRS tachycardia at any age, although
a heart rate of 150 complexes/min suggests atrial flutter with 2:1
heart block. There is no particular heart rate which excludes VT
or supraventricular tachycardia. Either arrhythmia may be fast
or relatively slow. Occasionally patients with fast tachycardia
are alert and conversational despite rapid VT and underlying
ventricular dysfunction. Presumably this results from an optimal balance of a low cardiac output and adequate peripheral
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vasoregulation to maintain cerebral perfusion. In patients with
an acute MI, it is prudent to assume the tachycardia is ventricular until proven otherwise, but these patients also frequently
have supraventricular arrhythmia. Some patients have both.
Ventriculoatrial dissociation is diagnostic for VT, but ventriculoatrial association may occur in either supraventricular
tachycardia or VT with I : I retrograde conduction. A single-lead
electrocardiographic monitoring strip is diagnostic of VT when
the QRS and P-wave morphologies are distinct and ventriculoatrial dissociation is apparent. Since wide QRS complexes are
usually tall, as well as wide, it is often difficult to discem the
smaller P waves on emergency or bedside monitoring equipmenl because they are buried within the QRS complex or a
broad T wave. A fortuitously timed sinus beat may capture the
ventricle resulting in occasional ventricular capfw/ e beats which
are narrow and look like sinus beats (because they are) during
the tachycardia. Such sinus beats which occur later in electrical
diastole may resull in ventricular/MS/O/? beats which are a morphologic hybrid of sinus and tachycardia QRS complexes.
Recording three or more electrocardiographic leads simultaneously allows comparison of barely perceptible P waves in
several leads and may clarify presence or absence of any temporal relationship to the QRS complexes. If there is a 1:1 relationship with normal P waves preceding each QRS complex, sinus
rhythm or other atrial rhythm is present. If there is AV dissociation (i.e., atrial and ventricular activity are independent), then
VT is diagnosed. If there is a 1:1 relationship wilh inverted P
waves following each QRS complex, either VT with retrograde
conduction or supraventricular tachycardia may be present.
A standard 12-lead ECG should be recorded during tachycardia whenever possible. It provides 1) a better "fingerprint" of the
arrhythmia (35,36), and 2) greater likelihood of detecting P
waves, and 3) the QRS morphology may be useful to discriminate tachycardia of supraventricular or ventricular origin. A
QRS width greater than 140 msec is highly suggestive of a VT.
Leftward deviation of the mean QRS vector is also highly correlated with VT. Capture beats and fusion beats, although diagnostic of VT, are relatively uncommon (37). A "concordant pattem" of precordial complexes (i.e., all leads in VI to V6 are entirely upright or entirely inverted) is highly suggestive of VT,
but is not common. In the presence of antegrade conduction over
an accessory AV pathway, the ventricle is activated ectopically
and such supraventricular tachycardia cannot be distinguished
from VT by surface electrocardiography. Furthermore, presence
of delta waves in the resting ECG by no means excludes the possibility of VT.
If the mechanism of the arrhythmia remains unclear, positioning of chest leads one interspace higher or lower or on the back
(nearer to the left atrium) may reveal P waves. When stable, a
"pill electrode" may be swallowed into the esophagus during the
tachycardia to record at the level of the left atrium. Otherwise a
temporary pacing wire may be passed through a nasogastric
tube.
The most reliable method of deiection of atrial activity during
tachycardia is to record the righl intraatrial electrogram by inserting a temporary pacing wire transvenously with fluoroscopic guidance, or a balloon-tipped electrode catheter with
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electrocardiographic monitoring while the proximal portion of
the lead is connected to lead V I . A quadripolar catheter allows
simultaneous recording and pacing.
In addition to passive recording, a pacing lead allows olher diagnostic and therapeutic interventions. Atrial pacing at rates exceeding the tachycardia rate can artificially produce the phenomena of atrial capture beats and fusion beats with transient
normalization or near-normalizafion of the QRS complexes.
The latter method may also allow for termination of the tachycardia by pacing in the atrium. Theoretically, atropine or isoproterenol, by enhancing AV nodal conduction, may facilitate
capture and fusion beats but could cause degeneration of the
tachycardia to ventricular fibrillation. Many supraventricular
tachycardias can be terminated by atrial entrainment, but this is
not absolutely diagnostic as relatively slow VTs may also be terminated by impulses conducted across the AV node. If the
tachycardia is ventricular in origin, the electrode catheter may
be advanced across the tricuspid valve to the right ventricular
apex to provide a stable position to attempi to entrain and terminate VT
Carotid sinus massage may slow or terminate AV nodal or
AV reentrant supraventricular tachycardia. It may result in AV
nodal block and dissociate the ventricles from the atria during
supraventricular tachycardias which originate in the atrium or
high within the AV node (sinus node reentry, intraatrial reentry,
atrial flutter or fibrillation, or automatic atrial tachycardia). P
waves may become apparent. A functional (rate-dependent)
bundle branch block may resolve.
Careful observaiion of any change in the tachycardia rate or
termination by an antiarrhythmic drug can be of diagnostic and
therapeutic value. Intravenous lidocaine is uniquely effective
for VT; it has no efficacy for atrial tachycardias nor reentry over
an accessory AV pathway. This specificity has diagnostic value.
Intravenous propranolol, verapamil, diltiazem, or digitalis glycosides slow AV nodal conduction. Hence, a tachycardia whose
mechanism depends on anterograde or retrograde AV nodal conduction will become slower and more tolerable. If intermittent
AV nodal block is produced, the tachycardia will terminate.
Digitalis glycosides are the least likely to exacerbate hypotension and are preferred if there is evidence of heart failure. The
disadvantage is the slow onset of action, even when administered intravenously, which makes them undesirable if the patient is rapidly deteriorating.
Calcium channel antagonists (verapamil or diltiazem) and Padrenergic blockers (propranolol) are contraindicated if the patient is hypotensive or has evidence of heart failure (35,38).
However, if there is no evidence of fluid overload or heart failure, it is valuable to administer about 200 mL of normal saline
(0.9% aqueous sodium chloride) intravenously to achieve an
adequate intravascular volume and decrease baroreceptor drive
for tachycardia. This often corrects hypotension, relieves anxiety, slows supraventricular tachycardia rate, and occasionally
allows spontaneous resolution of tachycardia. If the blood pressure is normal or high, calcium channel antagonists or p-adrenergic blockers may be safely given with negative dromotropic effect similar to the digitalis glycosides but more rapid in
onset and easier to titrate.
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Adenosine, when administered intravenously, blocks AV nod"Wide complex tachycardia" is a syndrome with many clinial conduction rapidly. It is metabolized rapidly in plasma and
cal presentations and several potential underiying mechanisms.
humantissues.Therefore, its duration of action is brief (about 5
It may or may not be associated with structural underlying carminutes). Advantages are rapid termination of supraventricular
diovascular disease, may be relatively benign, or may result
tachycardia and brief duration of hypotension or other side efin sudden death (35,38). The patient must always be evaluated
fects like facialflushing(39).
promptly, but critical data must also be gathered emergentiy in
Esmolol, an ultrashort-acting p-adrenergic blocking agent,
order to assure good long-term diagnostic and therapeutic accualso offers the opportunity to observe a brief effect on AV nodal racy. Wide complex tachycardia is a most challenging phenomconduction and termination of supraventricular tachycardia
enon for the cardiologist or electrophysiologist, but alert parawhile minimizing any residual side effect.
medics, nurses, house officers, and acute care physicians proIf the patient has a wide complex tachycardia and has a hisvide the cmcial and irretrievable initial data base which undertory of the Wolf-Parkinson-White syndrome, delta waves on
lies successful long-term management.
the ECG in sinus rhythm, or is young without underiying cardiovascular disease, particularly with a left bundle branch block
morphology, tachycardia mediated by conduction over an acVentricular Arrhythmia
cessory AV pathway must be considered. If an AV nodal blockSustained VT is arbitrarily defined by most experts as a
ing agent is administered and atrial fibrillation ensues, rapid
tachycardia of ventricular origin which, if unintermpted, perconduction over the accessory pathway can be catastrophic and
sists continuously for at least 30 seconds, or is intentionally tereven degenerate to ventricular fibrillation requiring cardioverminated earlier by cardioversion because of impending hemosion (40-43). In such patients, intravenous procainamide is the
dynamic collapse. Sustained VT may be terminated by intraveagent of choice because it may effectively block the accessory
nous lidocaine or procainamide, but generally requires cardiopathway and thereby slow or terminate AV reentry or atrial fiversion.
brillation or fiutter. Procainamide is also effecfive for terminaIn the patient with acute ischemic syndromes or evolving MI,
tion of VT
nonsustained VT should be suppressed because it is frequently a
A variety of guidelines have been published to help determine
harbinger of ventricular fibrillation.
the mechanism of the tachycardia based upon the QRS morpholTorsade de pointes, which literally means "turning around the
ogy on the 12-lead ECG. It should be compared side-by-side
point," is a descriptive, not a mechanistic, term for a polymorwith the resting ECG in sinus rhythm. If the patient has aberrant
phic VT which appears to tum above and below the isoelectric
conduction with a wide QRS morphology in sinus rhythm, aberaxis (46). More simply, some QRS complexes appear upright
ration will be presenl during supraventricular tachycardia. Iflhe
and some appear inverted. It is usually too fast, however, to acQRS morphology is similar during sinus rhythm and tachycarcurately distinguish the QRS (ventricular depolarization) from
dia, the tachycardia origin is probably supraventricular.
the T wave (ventricular depolarization) and hence the negative
The diagnosis can be made electrophysiologically if the padeflections might be T waves or vice versa. Torsade de pointes,
tient is stable enough for safe transport to the laboratory during as originally described, is nonsustained or self-terminating, usuthe arrhythmia to allow insertion of a catheter across the tricus- ally within several seconds. This is the major electrocardiopid valve to record a His-bundle electrogram. Otherwise the
graphic distinction from ventricular fibrillation which is rarely
tachycardia may be electively induced in the laboratory at a later
(some say never) self-terminafing.
time. A supraventricular tachycardia is recognized electrophysiTorsade de pointes is a syndrome and as such requires further
ologically by the presence of a His-bundle potential preceding
clinical data to determine appropriate therapy (47). It is associeach QRS complex with an H-V interval equal to or exceeding
ated with drug toxicity or proarrhythmia, electrolyte imbalance,
that recorded when the patient is in sinus rhythm. In contrast,
acute ischemia, coronary reperfusion, intracranial disease, or
during VT, the H-V interval, if a His-bundle potential is recongenital long QT syndrome. It is sometimes related to clinical
corded, is shorter than normal. More commonly, the His-bundle
bradycardia. The therapy begins with correction of any reverspotential is buried within the QRS complex during VT and canible exacerbating factors and discontinuation of any antiarrhythnot be discemed even on a recording from a catheter properiy
mic drugs. If rapidly recurrent, isoproterol infusion at a rate of 1
positioned to record the His-bundle electrogram. This phenometo 3 |ig/min, titrated upward to increase the resting sinus heart
non may also be observed during antegrade conduction over an
rate to a maximum of 100 beats/min, may suppress torsade de
accessory AV pathway (preexcitation syndrome) during atrial
pointes. When time permits, placement of a temporary transtachycardia or antidromic AV reentrant supraventricular tachyvenous pacemaker allows more precise control ofthe heart rate
cardia.
and suppression of arrhythmia. There is some theoretic basis for
Each patient with sustained monomorphic VT, in the absence
this therapy ifthe arrhythmia is due to eariy afterdepolarizations
of acute MI or other reversible cause, a reasonable quality of
which are suppressed in cellular preparations by pacing.
life, and a reasonable life expectancy of at least six months,
Ventricular fibrillation is the most serious of the cardiac
should undergo a diagnostic cardiac catheterization and coroarrhythmias and is invariably lethal if not promptly reversed or
nary angiography to determine any correctable anatomic etiolounless the patient is supported by effective cardiopulmonary regies (44). Thereafter, electrophysiologic testing can delermine
suscitation. The only effective therapy is asynchronous DC carthe mechanism and appropriate therapy (45).
dioversion with 100 to 360 joules. If ineffective, resuscitative
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efforts should continue while improving oxygenation, acid-base
slatus, coronary blood flow, and electrolytes. Cardioversion
may then be repeated. Clinically, coarse fibrillation seems more
easy to terminate. If fine fibrillation prevails, administration of
epinephrine may "coarsen" the undulations on the surface ECG
and facilitate cardioversion. Various experts advocate intravenous, intracardiac, or intratracheal administration. Some studies
have shown that cardiac levels may be adequate with intravenous or intratracheal administration, avoiding the risks of cardiac, pericardial, or pleural laceration, but controversy prevails
and it is common to administer intracardiac epinephrine for otherwise refractory fine ventricular fibrillation or asystole. Calcium chloride, 5 to 8 mg intravenously, may also be useful (48).
Premature ventricular depolarizations are exacerbated by the
same factors as any other arrhythmia. In coronary care units and
in survivors after MI there is a certain correlation with early
mortality, usually due to sudden arrhythmic cardiac death (4951). Such arrhythmias during acute MI should be suppressed
with intravenous lidocaine or procainamide. Interestingly, related symptomatology does not serve to distinguish benign from
malignant premature ventricular depolarizations. Although premature ventricular complex (PVC) frequency and complexity,
particularly in the presence of left ventricular dysfunction, is
highly associated with risk of early mortality after hospital discharge, chronic suppression of PVCs has not been shown to diminish the risk.
Originally the clinical diagnosis of acute MI was almost synonymous with sudden cardiac death; survivors were few. The
ability to monitor cardiac arrhythmia and lo defibrillale and the
development of specialized coronary care units and personnel
resulted in a significant population of survivors. Many of these
patients, however, remained at risk for sudden death over a period of several years despite retum to a functional life-style.
Studies to determine the predictors of risk were conducied by
cardiologists and often funded by insurance firms. All studies
showed that the most common cause of sudden cardiac death in
survivors of MI was VT or ventricular fibrillation. The most reliable predictor for risk stratification during periods of relative
health was presence of PVCs. Left ventricular dysfunction as
measured by the ejection fraction was also an independent predictor.
More delailed analysis of substrata, however, showed that the
PVC was a somewhat nonspecific marker. Therapy directed at
all patients with PVCs would treat far more patients than appeared actually to be at risk. Several algorithms were developed
based upon frequency of PVCs and/or complexity.
Complexity was defined by the presence of at least one of
.several criteria. One of these was the "R on T phenomenon"
which describes occurrence of an early PVC on top of the T
wave of the previous normal beat or in the vulnerable period
which had been determined in animal studies. This represenled
a period oftimein the relatively refractory period when the cells
had repolarized enough to be captured by such an early trigger,
yet the membranes had not yet achieved the normal resting potential. In these studies repetitive ventricular depolarizations,
nonsustained arrhythmia, and sustained VT or ventricular fibrillation might result.
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Another criterion for complexity was the presence of multifocal PVCs which were identified by varying PVC morphologies.
Although there is a possibility that PVCs from a single myocardial focus may have varying sites of exit and/or pattems of conduction resulting in varying QRS morphologies, this would be
difficult to prove by surface electrocardiography alone and
hence "multifocal" and "multiformed" are synonymous for clinical purposes.
"Repetitive" forms include pairs of PVCs and salvos or mns
of nonsustained VT. Nonsustained VT is defined as a self-terminating mn of VT consisting of three or more complexes. Some
investigators considered a frequency of 30 or more PVCs per
hour to be complex.
There are excellent data correlating complex PVCs with mortality in a number of large studies and hence the "PVC suppression hypothesis" was developed. In other words, it was assumed
that suppression of these lethal triggers could prevent sudden death in survivors of acute MI. Antiarrhythmic drugs were
then defined clinically by their ability to suppress spontaneous
PVCs. Without good data, the hypothesis was generalized to
justify the suppression of ectopy in other disease states (52) and
even apparentiy normal individuals without statistical proof of
risk.
In the absence of clinical trials to determine the effect of PVC
suppression on survival, the clinical praclice prevailed. There
were sporadic clinical data to suggest that suppression of PVCs
did not prove efficacy for prevention of the more important clinical goal of preventing sustained lethal tachyarrhythmias.
Josephson and Horowitz (53) popularized the electrophysiologic technique of triggering, or supplying, PVCs in a clinical
laboratory to detect a clinical substrate which could sustain a lethal tachycardia in patients with remote M l or inducible sustained VT. Electrophysiologic studies after acute MI are not yet
accepted in clinical centers in the United States.
Chronic suppression of such arrhythmias, if frequent and particularly if associated with runs of nonsustained VT, is probably
desirable. However, there is no proof that such chronic suppression prolongs survival, and each oral antiarrhythmic agent is associated with side effects and toxicity in a large number of patients.
In the Cardiac Arrhythmia Suppression Trial, suppression of
ectopy after Ml by type IC antiarrhythmic drugs was associated
with increased mortalily (54,55). Therefore, neither flecainide
nor encainide should be used for chronic PVC suppression after
MI.
Because of the uncertainty about the indications, benefits,
and risks of chronic antiarrhythmic therapy for high-risk survivors of MI, several randomized institutional trials are being conducted:
The Coronary Artery Bypass Graft/Patch(CABG/Patch) trial
is designed to determine the efficacy of the automatic implantable cardiovertor defibrillator (AICD) on all causes of mortality
or sustained ventricular arrhythmias in patients with low ejection fractions and no previous episode of cardiac arrest or sustained ventricular arrhythmia who are undergoing coronary artery bypass graft surgery. Quality of life and cost-effectiveness
substudies are being performed concurrently.
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The Multicenter Automatic Defibrillator Implantation Trial
(MADIT) is designed to determine if the survival of high-risk,
low ejection fraction, coronary artery disease patients with nonsustained VT and electrophysiologically inducible VT who have
not yet experienced sudden cardiac death or sustained VT can be
improved with AICD device therapy versus conventional medical management. The study will also include quality of life and
cost-effectiveness substudies.
The Multicenter Unsustained Tachycardia Trial (MUSTT) is
a North American study designed to determine if therapy guided
by electrophysiologic testing will reduce the risk of sudden cardiac death in patients with coronary artery disease and low ejection fraction who have nonsustained VT. The AICD device will
be used as adjunctive therapy in one limb of the study design.
The AICD cost-effectiveness trial is designed to determine if
the AICD device, when used as the therapy of first choice for
both MI patients and those who have survived cardiac arrest, is
a more effective treatment modality than conventional medical
evaluation and therapy.
At Henry Ford Hospital a study is currentiy being conducted
to assess psychological implications of AICD therapy as opposed to electrophysiologically guided medical therapy in patients who are effectively controlled on either regimen. The
study is neither randomized nor controlled. The purpose is to determine whether patients can or are likely to have an appropriate
sense of well-being with either or both types of therapy and also
give insight as to what psychological and teaching interventions
might be beneficial for this patient population.
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